3,272 research outputs found
Clinical Investigators' Day, March 19, 2012
No full textContents of this program booklet includes: Sponsors; Program Schedule; Keynote Speaker (Robert Gilmour); Speakers [faculty bio sketches]; Judges [bio sketches]; Moderators [bio sketches]; Investigators [bio sketches]
Clinical Investigators' Day, March 18, 2013
No full textContents of this program booklet includes: Sponsors; Program Schedule; Keynote Speakers (Luciano Souza Caixeta; Kelly Hume); Speakers [faculty bio sketches]; Judges [bio sketches]; Moderators [bio sketches]; Investigators [bio sketches]
Clinical Investigators' Day, October 5, 2018
No full textContents of this program booklet include: Welcome; Organizing Committee; Sponsors; Current CVM Clinical Trials; Program Schedule; Keynote Speaker (Gerlinde Van DeWalle); Guest Speaker (Jessica McArt); Moderators [bio sketches]; Judges [bio sketches]; Investigators [bio sketches]; Notes
Clinical Investigators' Day, October 10, 2014
No full textContents of this program booklet includes: Sponsors; Program Schedule; Keynote Speaker (Maria Constanca Matias Ferreira Pomba); Speakers [faculty bio sketches]; Judges [bio sketches]; Moderators [bio sketches]; Investigators [bio sketches]
Clinical Investigators' Day, September 30, 2016
No full textContents of this program booklet includes: Sponsors; Current Clinical Trials; Program Schedule; Keynote Speaker (John H. Rossmeisl); Speakers [faculty bio sketches]; Judges [bio sketches]; Moderators [bio sketches]; Investigators [bio sketches]
Clinical Investigators' Day, October 6, 2017
No full textContents of this program booklet include: Welcome; Sponsors; Current CVM Clinical Trials; Program Schedule; Keynote Speaker (Laura B. Goodman); Guest Speaker (Erica Behling-Kelly); Moderators [bio sketches]; Judges [bio sketches]; Investigators [bio sketches]; Notes
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
No full textBACKGROUND: PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but positive randomised data supporting their use as a first-line treatment are lacking. In this study we assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemotherapy for patients with previously untreated advanced urothelial carcinoma.
METHODS: KEYNOTE-361 is a randomised, open-label, phase 3 trial of patients aged at least 18 years, with untreated, locally advanced, unresectable, or metastatic urothelial carcinoma, with an Eastern Cooperative Oncology Group performance status of up to 2. Eligible patients were enrolled from 201 medical centres in 21 countries and randomly allocated (1:1:1) via an interactive voice-web response system to intravenous pembrolizumab 200 mg every 3 weeks for a maximum of 35 cycles plus intravenous chemotherapy (gemcitabine [1000 mg/m2] on days 1 and 8 and investigator's choice of cisplatin [70 mg/m2] or carboplatin [area under the curve 5] on day 1 of every 3-week cycle) for a maximum of six cycles, pembrolizumab alone, or chemotherapy alone, stratified by choice of platinum therapy and PD-L1 combined positive score (CPS). Neither patients nor investigators were masked to the treatment assignment or CPS. At protocol-specified final analysis, sequential hypothesis testing began with superiority of pembrolizumab plus chemotherapy versus chemotherapy alone in the total population (all patients randomly allocated to a treatment) for the dual primary endpoints of progression-free survival (p value boundary 0·0019), assessed by masked, independent central review, and overall survival (p value boundary 0·0142), followed by non-inferiority and superiority of overall survival for pembrolizumab versus chemotherapy in the patient population with CPS of at least 10 and in the total population (also a primary endpoint). Safety was assessed in the as-treated population (all patients who received at least one dose of study treatment). This study is completed and is no longer enrolling patients, and is registered at ClinicalTrials.gov, number NCT02853305. [...
Clinical Investigators' Day, November 6, 2020
No full textClinical Investigators' Day resident research symposium is held annually at the Cornell University College of Veterinary Medicine. This event provides an opportunity for residents and interns to hone both written and oral presentation skills and to showcase the breadth and depth of their ongoing clinical investigations being conducted in various areas of study. topics cover a wide range of applied, basic, retrospective and prospective studies.Contents of this program booklet include: Welcome; Organizing Committee; Sponsors; Current CVM Clinical Trials; Program Schedule; Keynote speaker (Heidi Reesink); Moderators [bio sketches]; Judges [bio sketches]; Investigators [bio sketches
Clinical Investigators' Day, April 14, 2023
No full textClinical Investigators' Day resident research symposium is held annually at the Cornell Veterinary College of Veterinary Medicine. this event provides an opportunity for residents and interns to hone both written and oral presentation skills and to showcase the breadth and depth of their ongoing clinical investigations being conducted in various areas of study. Topics cover a wide range of applied, basic, retrospective and prospective studies.Contents of this program booklet include: Welcome; Organizing Committee; CVM Centers Spotlight; Program Schedule; Keynote Speaker (Nicole Buote); Moderators [bio sketches]; Judges [bio sketches]; Investigators [bio sketches
Clinical Investigators' Day, April 1, 2022
No full textClinical Investigators' Day resident research symposium is held annually at the Cornell University College of Veterinary Medicine. This event provides an opportunity for residents and interns to hone both written and oral presentation skills and to showcase the breadth and depth of their ongoing clinical investigations being conducted in various areas of study. Topics cover a wide range of applied, basic, retrospective and prospective studies.Contents of this program booklet include: Welcome; Organizing Committee; Sponsors; Current CVM Clinical Trials; Program Schedule; Keynote Speaker (Sabine Mann); Moderators [bio sketches]; Judges [bio sketches]; Investigators [bio sketches
- …
